Prostate cancer is the most common cancer in men. In 2014 (the most recent year for which numbers are available) 172,258 men in the U.S. were diagnosed with prostate cancer and 28,343 men in the U.S. died from prostate cancer (Centers for Disease Control and Prevention, 2018). Medigen is using the advanced RNA VLP [...]

2018-05-07T18:42:07+00:00April 2nd, 2018|

Dengue and Zika

Dengue and Zika viruses are mosquito-borne flaviviruses related to Japanese encephalitis and yellow fever viruses. Estimates indicate ~400 million of dengue infections per year, of which ~100 million show clinical signs. Approximately 3.9 billion people in 128 countries are at risk of infection. There are 4 distinct serotypes of the virus. Recovery from infection [...]

2018-05-12T15:43:05+00:00April 2nd, 2018|

Yellow Fever

Yellow fever (YF) causes an acute hemorrhagic fever disease in tropical Africa and Latin America. The YF vaccine YF17D is available and is prepared in eggs. Shortages of the YF17D vaccine and rare adverse effects have been reported. To develop a novel YF vaccine, Medigen applied iDNA technology. The iDNA represents genetically stable DNA [...]

2018-05-07T18:41:12+00:00April 2nd, 2018|

Japanese encephalitis

Japanese encephalitis virus (JEV) is the main cause of viral encephalitis in many countries of Asia with an estimated 68,000 clinical cases every year and more than 3 billion people at risks of infection.  Medigen uses iDNA technology encoding synthetic, live-attenuated JEV vaccine. JEV iDNA can be used either directly for vaccination, or for [...]

2018-05-07T18:40:38+00:00April 2nd, 2018|

Lassa fever

Lassa fever is a hemorrhagic fever caused by the Lassa virus that commonly spreads to humans in Africa from the rodent Mastomys natalensis. Symptoms include fever, weakness, headaches, muscle pain and bleeding from the mouth or gastrointestinal tract. Once infected, the risk of death is about 1% and frequently occurs within two weeks of [...]

2018-05-07T18:39:24+00:00April 2nd, 2018|

Research on Lassa vaccine published

Lassa virus (LASV) is found primarily in West Africa, causing an estimated 500,000 cases and 5,000 deaths per year.  Scientists from the University of Louisville (Louisville, KY) and Medigen (Frederick, MD) described experimental LASV vaccines derived from the TC83 human IND vaccine.  The vaccines included RNA vector expressing glycoproteins (GPC) derived from distantly related [...]

2018-05-11T15:59:05+00:00January 29th, 2018|